(Attachment)

IMPORT / EXPORT STIMULANTS RAW MATERIALS BY CARRYING

Any person who intends to enter Japan carrying Stimulants Raw Materials (Appendix 1) for his / her own medical use is required to obtain an advance permission from the Director-General of one of the eight Regional Bureaus of Health and Welfare, JAPAN based on the Stimulants Control Act ".

Stimulants Raw Materials can not be imported / exported for treatment of the addiction.

Described below are the necessary procedures for obtaining an advance permission from the Director-General, Regional Bureau of Health and Welfare, JAPAN to enter / leave Japan carrying Stimulants Raw Materials for his / her medical use.

1 Procedures:

The following documents should be submitted to Narcotics Control Department of one of the eight Regional Bureaus of Health and Welfare in advance.

URL: http://www.ncd.mhlw.go.jp/en/application.html

2 Required documents:

1) Application form (Appendix 2-1, 2-2)

* When the re-import (re-export) of the Stimulants Raw Materials are foreseen, separate application forms for the import (required for entering Japan carrying Stimulants Raw Materials) and for the export (required for departing Japan carrying Stimulants Raw Materials) should be submitted together.

* The estimated quantity of Stimulants Raw Materials remaining at the point of departure should be indicated in the application form for the re-export.

2) Medical certificate

A medical certificate by his / her doctor identifying the disease, the necessity of Stimulants Raw Materials for his / her treatment, the names of Stimulants Raw Materials and their quantities prescribed should be submitted together with the application forms.

3 Two weeks is necessary to process the application. In case of urgency, please send by fax the application forms with medical certificate at least two weeks before your arrival / departure in / from Japan.

(The original forms should still be sent by air-mail.)

EquationThe informationEphedrine (Excluding any substance containing 10% or lessGral medicines that don't fall under the "stimulants" raw materials" and contain 10% or less ephedrine are marketed in Japan)Coughing, nasal congestionChloroephedrine(oral medicines, suppositories, and injections that don't fall under the "stimulants" raw materials" and contain 10% or less methylephedrine are marketed in Japan)Coughing, nasal congestionMethylephedrine (Excluding any substance containing 10% or less Methylephedrine)(oral medicines, suppositories, and injections that don't fall under the "stimulants" raw materials" and contain 10% or less methylephedrine are marketed in Japan)Coughing, nasal congestion, hives, rash ongestion, hives, rash or less methylephedrine are marketed in Japan)Chloromethylephedrine[Dimethylpropamine[Phenylacetic acid (Excluding any substance containing 10% or less Phenylacetoacetonitrile[Phenylacetoacetonitrile[Phenylacetone[Selegiline[Selegiline[Norephedrine (Excluding any substance containing 50% or less Norephedrine)[Norephedrine (Excluding any substance containing 50% or less Norephedrine)[Treatment for attention deficit hyperactivity disorder Australia)[Treatment for attention deficit hyperactivity disorder (AD/HD)[Graphenylacetoacetamide[ApAA[substance name	Examples of the names of the medicines	Main medical use
Methylephedrine (Excluding any substance containing 10% or less Methylephedrine)(oral medicines, suppositories, and injections that don't fall under the "stimulants' raw materials" and contain 10% or less methylephedrine are marketed in Japan)Coughing, nasal congestion, hives, rashChloromethylephedrineDimethylpropaminePhenylacetic acid (Excluding any substance containing 10% or less PhenylacetoacetonitrilePhenylacetoacetonitrilePhenylacetoneSelegilineFP-OD tablets (in Japan), Zelapar (America)Treatment for Parkinson diseaseNorephedrine)LisdexamfetamineVyvanse(in Japan) Vyvanse (North America, Australia)Treatment for attention deficit hyperactivity disorder (AD/HD)q-phenylacetoacetamide	(Excluding any substance containing 10% or less Ephedrine)	(oral medicines that don't fall under the "stimulants' raw materials" and contain 10% or less ephedrine are	
Methylephedrine (Excluding any substance containing 10% or less Methylephedrine)suppositories, and injections that don't fall under the "stimulants' raw materials" and contain 10% or less methylephedrine are marketed in Japan)Coughing, nasal congestion, hives, rashChloromethylephedrineDimethylpropaminePhenylacetic acid (Excluding any substance containing 10% or less PhenylacetoacetonitrilePhenylacetoacetonitrilePhenylacetoneSelegilineFP-OD tablets (in Japan), Zelapar (America)Treatment for Parkinson diseaseNorephedrine)LisdexamfetamineVyvanse(in Japan) Vyvanse (North America, 	Chloroephedrine		
DimethylpropamineImage: Constraint of the sector of the sect	(Excluding any substance containing 10% or less	suppositories, and injections that don't fall under the "stimulants' raw materials" and contain 10% or less methylephedrine are	
Phenylacetic acid (Excluding any substance containing 10% or less Phenylacetic acid)Image: Content of the set of the	Chloromethylephedrine		
(Excluding any substance containing 10% or less Phenylacetic acid)Image: containing 10% or less PhenylacetonePhenylacetoacetonitrileImage: containing 10% or lessPhenylacetoneImage: containing 50% or less 	Dimethylpropamine		
PhenylacetoneFP-OD tablets (in Japan), Zelapar (America)Treatment for Parkinson diseaseNorephedrine (Excluding any substance containing 50% or less Norephedrine)FP-OD tablets (in Japan), Zelapar (America)Treatment for Parkinson diseaseNorephedrine (Excluding any substance containing 50% or less Norephedrine)Treatment for attention deficit hyperactivity disorder (AD/HD)LisdexamfetamineVyvanse (North America, Australia)Treatment for attention deficit hyperactivity disorder (AD/HD)	(Excluding any substance containing 10% or less		
SelegilineFP-OD tablets (in Japan), Zelapar (America)Treatment for Parkinson diseaseNorephedrine (Excluding any substance containing 50% or less Norephedrine)	Phenylacetoacetonitrile		
SelegilineZelapar (America)Parkinson diseaseNorephedrine (Excluding any substance containing 50% or less Norephedrine)	Phenylacetone		
(Excluding any substance containing 50% or less Norephedrine)Image: Containing 50% or less Norephedrine)Image: Containing 50% or less Norephedrine)LisdexamfetamineVyvanse(in Japan) Vyvanse (North America, Australia)Treatment for attention deficit hyperactivity disorder (AD/HD)α-phenylacetoacetamideImage: Containing to the test of test	Selegiline	- ·	
Lisdexamfetamine Vyvanse(in Japan) Vyvanse (North America, Australia) attention deficit hyperactivity disorder (AD/HD) α-phenylacetoacetamide	(Excluding any substance containing 50% or less		
		Vyvanse (North America,	attention deficit hyperactivity disorder
APAA	α-phenylacetoacetamide		
	APAA		

Stimulants' Raw Material (Stimulants Control Act)

APPLICATION FORM(IMPORT)

This format to be used in applying for permission to **import** Stimulants Raw Mate rials by carrying.

	Name of Stimulants Raw Materials	Quantity
Stimulants Raw		
Materials to be		
imported by carrying		
Reason for the entry into Japan		
Reason for the necessity		
for Stimulants Raw		
Materials use		
Time of entry into		
Japan		
Name of port of entry		
As stated above, I he	reby apply for permission to imp	oort Stimulants Raw Materials
by carrying.		
Date:		
Address:		
Phone:	Fax:	
E-mail:		
Name:	Signature:	
To: Director-General		
R	egional Bureau of Health and	Welfare

* This form should be typed or printed.

APPLICATION FORM(IMPORT)

This format to be used in applying for permission to **import** Stimulants Raw Mate rials by carrying.

Tais by carrying.	Name of Stimulants Raw Materials	Quantity
Stimulants Raw Materials to be imported by carrying	**** 30mg (Lisdexamfetamine)	10 tabs (300mg)
Reason for the entry into Japan	To attend the International Conference of ABC	
Reason for the necessity for Stimulants Raw Materials use	As treatment for an illness	
Time of entry into Japan	20 April 2020	
Name of port of entry	Narita International Airport	
by carrying. Date: 20 March 2020	reby apply for permission to imp ngton, St. New York U.S.A	oort Stimulants Raw Materials
Phone: 1-123-456-7890 Fax: 1-123-456-9999 E-mail: abcde@fg.hi Name: Sherlock Holmes Signature:		
To: Director-General Kanto-Shin'etsu Regional Bureau of Health and Welfare This form should be typed or printed.		

* This form should be typed or printed.

APPLICATION FORM(EXPORT)

This format to be used in applying for permission to **export** Stimulants Raw Mater ials by carrying.

	Name of Stimulants Raw Materials	Quantity
Stimulants Raw		
Materials to be		
exported by carrying		
Reason for departure		
from Japan		
Reason for the		
necessity for		
Stimulants Raw		
Materials		
Time of departure		
from Japan		
Name of port of		
departure		
As stated above, I here	by apply for permission to export Stin	nulants Raw Materials by carrying.
Date:		
Address:		
Phone:	Fax:	
E-mail:		
Name:	Signature:	
To: Director-General		
Reg	ional Bureau of Health and Welf	are

* This form should be typed or printed.

APPLICATION FORM(EXPORT)

This format to be used in applying for permission to **export** Stimulants Raw Mater ials by carrying.

als by carrying.	Name of Stimulants Raw Materials	Quantity
Stimulants Raw Materials to be exported by carrying	**** 2.5mg (Lisdexamfetamine)	10 tabs or less (25mg or less)
Reason for departure from Japan	To return to my country	
Reason for the necessity for Stimulants Raw Materials	As treatment for an illness	
Time of departure from Japan	25 April 2020	
Name of port of departure	Narita International Airport	
As stated above, I herek	y apply for permission to export Stir	nulants Raw Materials by carrying.
Date: 20 March 2020 Address: A-123, Wash	ington, St. New York U.S.A	
Phone: 1-123-456-7890 Fax: 1-123-456-9999		
E-mail: abcde@fg.hi		
Name: Sherlock Holm	es Signature:	
To: Director-General Kanto-Shin'etsu Re	gional Bureau of Health and	Welfare
This form should be t	yped or printed.	

List of Narcotics Control Department, Regional Bureau of Health and Welfare

Name of Narcotics Control Department	Location, Telephone, Facsimile	Area in charge
Department,	〒060-0808 1-1, Nishi 2 chome, Kita 8 jo, Kita-ku Sapporo-shi tel:81-11-726-3131 fax:81-11-709-8063 mail: sapporoncd@mhlw.go.jp	Hokkaido
Department, Tohoku	〒980-0014 2-23, Hon-cho 3 chome, Aoba-ku, Sendai- shi tel:81-22-221-3701 fax:81-22-221-3713 mail: sendaincd@mhlw.go.jp	Aomori, Iwate, Miyagi, Akita Yamagata, Fukushima
Department, Kanto-Shin'etsu	〒102-8039 2-1, kudanminami 1chome, chiyoda-ku, Tokyo-to tel:81-3-3512-8691 fax:81-3-3512-8689 mail: tokyoncd@mhlw.go.jp	Ibaraki, Tochigi, Gunma, Saitama, Chiba, Tokyo, Kanagawa, Yamanashi, Nagano, Niigata
Department, Tokai Hokuriku	〒460-0001 5-1, Sannomaru 2 chome, Naka-ku, Nagoya-shi tel:81-52-951-6911 fax:81-52-951-6876 mail: nagoyancd@mhlw.go.jp	Shizuoka, Aichi, Mie, Gifu, Toyama, Ishikawa
	⊤540-0008 1-76, Otemae 4 chome, Chuo-ku, Osaka-	Fukui, Shiga, Kyoto, Osaka, Hyogo, Nara, Wakayama
Department, Chugoku-Shikoku Regional Bureau of <u>Health and Welfare</u> Narcotics Control Department, Shikoku Regional	〒730-0012 6-30, Kami-Hacchobori, Naka-ku, Hiroshima-shi tel:81-82-227-9011 fax:81-82-227-9174 mail: hiroshimancd@mhlw.go.jp	Tottori, Shimane, Okayama, Hiroshima, Yamaguchi Tokushima, Kagawa, Ehime, Kouchi
Department,	〒812-0013 10-7, Hakataeki Higashi 2 chome Hakata-ku, Fukuoka-shi tel:81-92-472-2331 fax:81-92-451-2336 mail: fukuokancd@mhlw.go.jp	Fukuoka, Saga, Nagasaki, Kumamoto, Oita, Miyazaki Kagoshima, Okinawa

Your application should be submitted to the Narcotics Control Department mentioned above.

* In case you will enter Japan; To the Narcotics Control Department in charge of the area where you will enter into Japan.

* In case you are hospitalized in Japan; To the Narcotics Control Department in charge of the area where the hospital is located.

* In case you live in Japan; To the Narcotics Control Department in charge of the area where your domicile is located.